Curis Inc. (NASDAQ:CRIS) has been given a $7.00 price target by analysts at RBC Capital Markets in a research note issued on Wednesday. The firm presently has a a “buy” rating on the stock. RBC Capital Markets’ price target points to a potential upside of 131.02% from the stock’s current price.

Several other brokerages also recently weighed in on CRIS. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 16th. FBR & Co reaffirmed a “buy” rating on shares of Curis in a research note on Thursday, September 8th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $7.00 target price on shares of Curis in a research note on Wednesday, September 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $5.05.

Analyst Recommendations for Curis (NASDAQ:CRIS)

Shares of Curis (NASDAQ:CRIS) traded down 1.32% during mid-day trading on Wednesday, reaching $2.99. The company had a trading volume of 398,057 shares. The stock’s 50-day moving average price is $2.26 and its 200 day moving average price is $1.87. The company’s market capitalization is $387.12 million. Curis has a 1-year low of $1.25 and a 1-year high of $3.42.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). The business earned $1.70 million during the quarter, compared to the consensus estimate of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The business’s quarterly revenue was down 19.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) EPS. Equities analysts expect that Curis will post ($0.37) EPS for the current year.

In other news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the transaction, the insider now owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.09% of the company’s stock.

Several hedge funds have recently modified their holdings of CRIS. Royal Bank of Canada boosted its stake in shares of Curis by 0.9% in the second quarter. Royal Bank of Canada now owns 811,129 shares of the company’s stock valued at $1,265,000 after buying an additional 7,220 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Curis during the second quarter valued at approximately $146,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Curis during the second quarter valued at approximately $312,000. Barclays PLC boosted its stake in shares of Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Curis by 8.7% in the second quarter. State Street Corp now owns 1,579,103 shares of the company’s stock valued at $2,464,000 after buying an additional 126,694 shares during the last quarter. Hedge funds and other institutional investors own 52.36% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.